Haave Hilde, Ljokjel Borghild, Lybak Helene, Moe Svein E, Berge Jan E, Vintermyr Olav K, Helgeland Lars, Aarstad Hans J
Department of Otolaryngology/Head and Neck Surgery, Haukeland University Hospital, 5020 Bergen, Norway.
Department of Pathology, Haukeland University Hospital, 5020 Bergen, Norway.
Biomedicines. 2022 Oct 5;10(10):2484. doi: 10.3390/biomedicines10102484.
Oropharynx squamous cell carcinoma (OPSCC) is of special interest because human papilloma virus (HPV) and/or smoking cause this disease. Influxes of inflammatory cells into such tumors are known to vary with prognoses.
To study whether the density of tumor-infiltrating T lymphocytes and tumor-infiltrating macrophages predicted general 20-year overall survival (OS), as well as OS with only disease-specific survival (DSS) patients included.
Biopsies from patients treated for OPSCC ( = 180) were stained by immunohistochemistry and the tumor cell macrophage (CD68), pan T lymphocytes (CD3), and regulatory T lymphocytes (Foxp3) densities were determined. The HE-determined percentage of matured tumor cells and the rate of invasion were calculated, and stromal desmoplasia were performed. Tumor HPV presence was studied by PCR. Twenty-year OS and five-year DSS patients were determined.
Tumor HPV status strongly predicted survival. High tumor infiltration of CD3, Foxp3 and CD68-positive cells predicted better twenty-year OS, with and without HPV stratification. Foxp3 and CD68 levels predicted OS, and 20-year among DSS patients, primarily among HPV(+) patients. Tumor HE-derived variables did not predict such survival.
Tumor HPV status, level of Foxp3 tumor-infiltrating lymphocytes and CD68 tumor-infiltrating macrophages predicted up to 20-year OS of both all patients and disease-specific survived patients.
口咽鳞状细胞癌（OPSCC）备受关注，因为人乳头瘤病毒（HPV）和/或吸烟会引发这种疾病。已知炎症细胞向此类肿瘤的浸润情况会因预后不同而有所差异。
研究肿瘤浸润性T淋巴细胞和肿瘤浸润性巨噬细胞的密度是否能预测20年总生存率（OS），以及仅纳入疾病特异性生存（DSS）患者时的OS。
对180例接受OPSCC治疗的患者进行活检，采用免疫组织化学染色，测定肿瘤细胞巨噬细胞（CD68）、全T淋巴细胞（CD3）和调节性T淋巴细胞（Foxp3）的密度。计算苏木精-伊红（HE）染色确定的成熟肿瘤细胞百分比和侵袭率，并进行间质纤维组织增生评估。通过聚合酶链反应（PCR）研究肿瘤HPV的存在情况。确定20年OS和5年DSS患者。
肿瘤HPV状态强烈预测生存率。CD3、Foxp3和CD68阳性细胞的高肿瘤浸润预测20年OS更好，无论是否进行HPV分层。Foxp3和CD68水平预测OS，以及DSS患者中的20年生存率，主要是在HPV（+）患者中。肿瘤HE衍生变量不能预测此类生存率。
肿瘤HPV状态、Foxp3肿瘤浸润淋巴细胞水平和CD68肿瘤浸润巨噬细胞可预测所有患者以及疾病特异性存活患者长达20年的OS。
